Objective-To see whether low dose thiazide diuretics given to patients with essential hypertension might avoid the adverse metabolic consequences seen with conventional doses.
Introduction
Thiazide diuretics were introduced into clinical practice in 1957.' Since then they have remained popular for arterial hypertension, providing an effective, well tolerated once daily treatment. They have been used in many large prospective clinical trials in mild hypertension, producing consistent benefit, particularly in reducing the excess risk of stroke. 24 However, thiazide diuretics are associated with several potentially deleterious metabolic effects.56 These include hypokalaemia, hyperuricaemia, short term hyperlipidaemia, impaired glucose tolerance, and an increased risk of diabetes. It has been proposed that these potentially detrimental effects may to some extent offset the benefit gained by blood pressure reduction.7 But many of these adverse effects are dose dependent and can be minimised by using lower doses. The effectiveness of low dose thiazide diuretics in the absence of adverse metabolic effects has been emphasised for bendrofluazide,8 cyclopenthiazide, 9 and hydrochlorothiazide."0 There are multiple risk factors for coronary artery disease in patients with hypertension before they receive any drug treatment."'-`Comparatively minor degrees of glucose intolerance comparable to those in many patients with hypertension significantly increase the risk of coronary artery disease.'4 Abnormalities of lipoprotein metabolism have also been described in patients with untreated hypertension." Hyperinsulinaemia is common in hypertension," 1 ' and it also may be a risk factor for coronary artery disease. '6 Finding impaired insulin action in essential hypertension before treatment'7 has led to suggestions that insulin resistance is an underlying metabolic defect in hypertension. Not only would this contribute to the rise in arterial blood pressure but it would also account for the range of observed abnormalities in carbohydrate, lipid, and lipoprotein metabolism so prevalent in hypertensive subjects. " Pollare et al found that hydrochlorothiazide in conventional dosage seemed to decrease insulin mediated glucose disposal.'8 Given this and the evidence promoting insulin resistance as a vascular risk factor, it has been argued that those antihypertensive drugs which improve insulin action should be used in preference to drugs such as thiazide diuretics which may adversely affect insulin sensitivity.
No information is available regarding the effects of low dose thiazide diuretics on insulin action. Furthermore, we know of only one study in which hepatic insulin sensitivity was assessed during thiazide treatment; that study used a conventional dose of cyclopenthiazide. ' A primed continuous infusion of high performance liquid chromatography purified [6-'H]glucose (New England Nuclear Research Products Division, Dupont Ltd, Stevenage, United Kingdom (NET lOOC)) was given during a two hour equilibration period (-120 minutes to zero time), after which a two hour continuous infusion of insulin (Humulin S; Eli Lilly and Co, Basingstoke) was begun at 1 mU/kg/min. Plasma glucose was maintained at the fasting concentration by an exogenous glucose infusion (20%). Exogenous glucose was prelabelled with [6-'H] glucose to match the predicted basal plasma glucose specific activity as described22 with the modification that the primed continuous tracer infusion was reduced to 50% of the basal rate after 20 minutes and to 25% of basal after 40 minutes (in order to maintain tracer steady state) and was maintained at this rate throughout the remainder ofthe hyperinsulinaemic period. ANALYTICAL 
TECHNIQUES
Arterialised venous blood was used for all analyses. Plasma for measurement of glucose specific activity was deproteinised with barium dihydroxide and zinc sulphate by the method of Somogyi.2' After centrifugation the supernatant was passed sequentially through anion (AG1-X8; BioRad Laboratories, Watford) and cation (AG50W-X8; BioRad) exchange columns to remove charged molecules. Samples were counted in a liquid scintillation spectrometer (Tri-Carb 2000 CA, Canberra Packard, Pangbourne). Aliquots of tracer infusate and labelled exogenous glucose infusion were spiked into non-radioactive plasma and processed in parallel with plasma samples to allow calculation of [6-3H] 3-7 (0-4)*t Urea (mmol/l) 5-4 (1-2) [5] [6] (1-5) (1-2) [5] [6] [7] (1-2) Creatinine (,molA) 88 (12) 90 (12) 88 (12) 90 ( -7) 7-3 (3-9)
8-5 (3-1)* Steady state clamp insulin (mU/I) 86 (10) 78 (12) 82 (11) Exogenous glucose infusion rate (90-120 min; pumoVkg/min) 22-9 (7-3)
23-1 (7-3) 21-5 (7-3) Postabsorptive endogenous glucose production (,umoVkg/min) 10-0 (0-8) 9-9 (0-8)t 10 9 (1-2)*t Endogenous glucose production during clamp Postabsorptive endogenous glucose production (an index of hepatic insulin sensitivity) increased significantly compared with baseline after treatment with 5 0 mg bendrofluazide whereas 1-25 mg had no such effect (table III) . Endogenous glucose production was significantly higher after 5 mg compared with 1 25 mg. After insulin endogenous glucose production was suppressed to a similar extent with both doses. Total glucose disappearance rates during the 1 0 mU/kg/min insulin infusion were not significantly different between doses.
Postabsorptive concentrations of serum non-esterified fatty acids, ,B-hydroxybutyrate, and glycerol were unchanged by treatment with either dose. During hyperinsulinaemia rapid suppression to a similar extent was seen with both doses (figure).
Discussion
Thiazide diuretics remain one of the most popular treatments for raised arterial blood pressure despite reports of their adverse effects on electrolyte, glucose, and lipid metabolism. If we are to continue to use them we must minimise adverse metabolic effects, and one way to do this is to use lower doses.
In this study reduction of blood pressure was similar after treatment with both low and conventional dose bendrofluazide. The magnitude of the antihypertensive effect after low dose bendrofluazide (17/10 mm Hg) was comparable to that reported in a much larger, parallel group study (13/10 mm Hg).8 Furthermore, we found low dose bendrofluazide to have no detrimental effects on peripheral or hepatic insulin action. By contrast, conventional dose bendrofluazide produces hepatic insulin resistance, as evidenced by hyperinsulinaemia and increased basal endogenous glucose production.
Thiazide diuretics in high dosage impair glucose tolerance and in some cases precipitate overt diabetes BMJ VOLUME 309 23 JULY 1994 mellitus.2829 These effects may be dose dependent.'0 Several mechanisms, including hypokalaemia'0 and reduced insulin secretion," have been proposed to explain the impaired carbohydrate metabolism during thiazide treatment. Finding peripheral insulin resistance in essential hypertension before drug treatment'7 has concentrated interest on the effects of various classes of antihypertensive agents on insulin sensitivity. An early report suggested that chlorothiazide interferes with the peripheral utilisation of glucose." Much later Pollare et al, using the euglycaemic glucose clamp technique, found that hydrochlorothiazide 40 mg daily causes an 11% reduction in insulin mediated glucose disposal. '8 In this study our hypertensive patients were insulin resistant at baseline compared with normal subjects studied previously.'9 Low dose bendrofluazide (1 25 mg) produced no change in peripheral insulin action compared with baseline. Though no differences between doses were observed, 5 0 mg bendrofluazide produced a 6% reduction in insulin mediated glucose disposal. This did not reach significance (P=0 1) and was in contrast with the findings of Pollare et al with an equivalent conventional dose. The possibility of a type II error exists in that the power of our study was sufficient to detect differences of around 10% at the 5% level of significance. Alternatively, effects on peripheral insulin action may vary with different thiazide diuretics. We have found that insulin mediated glucose disposal does not change after 12 weeks' treatment with cyclopenthiazide 500 ,ug.'9 What appears very clear from this study, however, is that a lower than conventional dose of bendrofluazide does not worsen the peripheral insulin resistance of patients with essential hypertension.
Whereas patients with essential hypertension have significant peripheral insulin resistance, hepatic insulin sensitivity seems to be largely preserved.'7"' Most studies of the effects of antihypertensive agents on insulin sensitivity have concentrated on peripheral insulin action, so that little information is available on effects on hepatic insulin sensitivity. We have detected a small but significant increase in basal endogenous (hepatic) glucose production (9%) with the use of conventional dose bendrofluazide. As basal insulin concentrations were also increased, this may represent induction of a degree of hepatic insulin resistance even though suppression of endogenous glucose production was not affected. We have noted a similar effect with the use of conventional doses of cyclopenthiazide.'9 Insulin induced suppression of lipolysis (as reflected in the suppression of non-esterified free fatty acids during hyperinsulinaemia) was not impaired by bendrofluazide 5 mg, indicating that hepatic insulin resistance does not extend to effects on lipid metabolism.
Significant hepatic resistance to insulin is a characteristic defect in glucose metabolism in non-insulin dependent diabetes mellitus, leading to increased hepatic glucose production both in the fasting state (roughly 20-25% with moderate hyperglycaemia) and after meals."-Increased hepatic glucose production may be an early and fundamental defect in non-insulin dependent diabetes.'6 The increase in hepatic glucose production with conventional dose thiazide diuretics could therefore be related to the increased incidence of impaired glucose intolerance and subsequent development of diabetes in patients with hypertension treated with these agents. However, it is clear from our study that with the use of low doses of bendrofluazide the deterioration in hepatic insulin action seen with more conventional doses is avoided.
A differential effect between doses was evident for serum potassium concentration. The dose-response nature of thiazide effects on serum potassium has been described. We are grateful to Dr C Patterson, department of community medicine and medical statistics, The Queen's University of Belfast, for statistical advice. We also thank Mr Noel Bell for the metabolite assays. During these studies Dr R Harper was a Royal Victoria Hospital research fellow.
Introduction
Peak bone mass in young adults is a major determinant of bone mass later in life.' Thus even though most osteoporotic fractures occur in elderly people, the risk of osteoporosis may be profoundly affected by events in early life. Genetic factors play a major part in the determination of peak bone mass, accounting for up to 80% of the variance,2 but 20% or more may be due to environmental factors, including exercise, smoking, and calcium intake.
The role of these lifestyle factors in adolescents and young adults as determinants of peak bone mass has, however, been examined in only a few studies,3"10 and environmental factors during youth were estimated by retrospective surveys,"7 an extremely crude method of assessment. Furthermore, bone mineral content or density was usually measured only at radial or vertebral sites'4 6-8 and not at the femoral sites, which are most important with regard to osteoporotic hip fractures later in life. To date, the role of calcium intake in achieving peak bone mass has been most convincingly supported by prospective interventional studies8 10 and that of exercise in a cross sectional study of children aged 5-14.9 The effect of smoking has not been studied in these age groups.
The cardiovascular risk in young Finns study was originally designed to obtain information on risk factors for coronary heart disease and their determinants in childhood. The study began in 1980 with
